{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:55:06Z","timestamp":1761580506886},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1007\/s11906-001-0067-x","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T16:48:06Z","timestamp":1180111686000},"page":"S17-S23","source":"Crossref","is-referenced-by-count":8,"title":["Differentiation in the Angiotensin II Receptor 1 blocker class on autonomic function"],"prefix":"10.1007","volume":"3","author":[{"given":"Henry","family":"Krum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"suppl 3","key":"67_CR1","first-page":"S11","volume":"17","author":"KH Rahn","year":"1999","unstructured":"Rahn KH, Barenbrock M, Hausberg M: The sympathetic nervous system in the pathogenesis of hypertension. J Hypertens 1999, 17(suppl 3):S11-S14.","journal-title":"J Hypertens"},{"key":"67_CR2","first-page":"507","volume":"6","author":"M Esler","year":"1984","unstructured":"Esler M, Jennings G, Korner P, et al.: Total, and organ-specific, noradrenaline plasma kinetics in essential hypertension. Clin Exp Hypertens [A] 1984, 6:507\u2013521.","journal-title":"Clin Exp Hypertens [A]"},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/00004872-199306000-00009","volume":"11","author":"JS Floras","year":"1993","unstructured":"Floras JS, Hara K: Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens 1993, 11:647\u2013655.","journal-title":"J Hypertens"},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/10641969609088965","volume":"18","author":"S Julius","year":"1996","unstructured":"Julius S: The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens 1996, 18:305\u2013321.","journal-title":"Clin Exp Hypertens"},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/00004872-199109000-00010","volume":"9","author":"S Guzzetti","year":"1991","unstructured":"Guzzetti S, Dassi S, Pecis M, et al.: Altered pattern of circadian neural control of heart period in mild hypertension. J Hypertens 1991, 9:831\u2013838.","journal-title":"J Hypertens"},{"issue":"suppl A","key":"67_CR6","doi-asserted-by":"crossref","first-page":"72A","DOI":"10.1016\/0735-1097(93)90466-E","volume":"22","author":"JS Floras","year":"1993","unstructured":"Floras JS: Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993, 22(suppl A):72A-84A.","journal-title":"J Am Coll Cardiol"},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00004872-199917060-00001","volume":"17","author":"G Grassi","year":"1999","unstructured":"Grassi G, Esler M: How to assess sympathetic activity in humans. J Hypertens 1999, 17:719\u2013734.","journal-title":"J Hypertens"},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1445-5994.1999.tb00737.x","volume":"29","author":"H Krum","year":"1999","unstructured":"Krum H: Sympathetic activation and the role of beta-blockers in chronic heart failure. Aust N Z J Med 1999, 29:418\u2013427.","journal-title":"Aust N Z J Med"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"15L","DOI":"10.1016\/S0002-9149(97)00845-X","volume":"80","author":"WS Colucci","year":"1997","unstructured":"Colucci WS: Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997, 80:15L-25L.","journal-title":"Am J Cardiol"},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","volume":"311","author":"JN Cohn","year":"1984","unstructured":"Cohn JN, Levine TB, Olivari MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819\u2013823.","journal-title":"N Engl J Med"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.HYP.34.4.724","volume":"34","author":"G Mancia","year":"1999","unstructured":"Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999, 34:724\u2013728.","journal-title":"Hypertension"},{"issue":"suppl 3","key":"67_CR12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0895-7061(98)00207-6","volume":"17","author":"P Palatini","year":"1999","unstructured":"Palatini P: Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens 1999, 17(suppl 3):S3-S10.","journal-title":"J Hypertens"},{"key":"67_CR13","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1111\/j.1440-1681.1996.tb02820.x","volume":"3","author":"GA Head","year":"1996","unstructured":"Head GA: Role of AT1 receptors in the central control of sympathetic vasomotor function. Clin Exp Pharmacol Physiol Suppl 1996, 3:S93-S98.","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"67_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(97)00861-5","volume":"772","author":"Y Hirooka","year":"1997","unstructured":"Hirooka Y, Potts PD, Dampney RA: Role of angiotensin II receptor subtypes in mediating the sympathoexcitatory effects of exogenous and endogenous angiotensin peptides in the rostral ventrolateral medulla of the rabbit. Brain Res 1997, 772:107\u2013114.","journal-title":"Brain Res"},{"key":"67_CR15","first-page":"R303","volume":"271","author":"H Murakami","year":"1996","unstructured":"Murakami H, Liu JL, Zucker IH: Blockade of AT1 receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am J Physiol 1996, 271:R303-R309.","journal-title":"Am J Physiol"},{"key":"67_CR16","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00004872-199917010-00005","volume":"17","author":"DP Brooks","year":"1999","unstructured":"Brooks DP, Ruffolo RR Jr: Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J Hypertens Suppl 1999, 17:S27-S32.","journal-title":"J Hypertens Suppl"},{"key":"67_CR17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1476-5381.1995.tb13313.x","volume":"114","author":"SL Cox","year":"1995","unstructured":"Cox SL, Ben A, Story DF, Ziogas J: Evidence for the involvement of different receptor subtypes in the pre-and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol 1995, 114:1057\u20131063.","journal-title":"Br J Pharmacol"},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.bjp.0701959","volume":"124","author":"S Guimaraes","year":"1998","unstructured":"Guimaraes S, Paiva MQ, Moura D: Different receptors for angiotensin II at pre-and postjunctional level of the canine mesenteric and pulmonary arteries. Br J Pharmacol 1998, 124:1207\u20131212.","journal-title":"Br J Pharmacol"},{"key":"67_CR19","first-page":"167","volume":"1","author":"H Krum","year":"1995","unstructured":"Krum H, Goldsmith RL: Effects of pharmacological therapy on autonomic function in patients with chronic heart failure. Editorials Cardiol 1995, 1:167\u2013176.","journal-title":"Editorials Cardiol"},{"key":"67_CR20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056\u20131064.","journal-title":"Circulation"},{"key":"67_CR21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00001573-199705000-00008","volume":"12","author":"HR Middlekauff","year":"1997","unstructured":"Middlekauff HR: Mechanisms and implications of autonomic nervous system dysfunction in heart failure. Curr Opin Cardiol 1997, 12:265\u2013275.","journal-title":"Curr Opin Cardiol"},{"issue":"12","key":"67_CR22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/00004872-199816120-00012","volume":"16","author":"G Grassi","year":"1998","unstructured":"Grassi G, Turri C, Dell\u2018Oro R, et al.: Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998, 16(12 Pt 1):1789\u20131796.","journal-title":"J Hypertens"},{"issue":"3","key":"67_CR23","first-page":"E415","volume":"272","author":"RH Worck","year":"1997","unstructured":"Worck RH, Ibsen H, Frandsen E, Dige-Petersen H: AT 1 receptor blockade and the sympathoadrenal response to insulininduced hypoglycemia in humans. Am J Physiol 1997, 272(3 Pt 1):E415-E421.","journal-title":"Am J Physiol"},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1161\/01.CIR.95.9.2286","volume":"95","author":"G Noll","year":"1997","unstructured":"Noll G, Wenzel RR, de Marchi S, et al.: Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 1997, 95:2286\u20132292.","journal-title":"Circulation"},{"key":"67_CR25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1172\/JCI117021","volume":"93","author":"B Clemson","year":"1994","unstructured":"Clemson B, Gaul L, Gubin SS, et al.: Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994, 93:684\u2013691.","journal-title":"J Clin Invest"},{"key":"67_CR26","doi-asserted-by":"crossref","unstructured":"Lyons D, Roy S, Kinirons M, Swift CG: Selective AT 1 receptor antagonism enhances sympathetically mediated vasoconstriction in the human forearm [abstract 6A.5]. Presented at the First International Symposium on Angiotensin II Antagonists, October 1997, London.","DOI":"10.1016\/S0895-7061(97)90862-1"},{"key":"67_CR27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.96.3.911","volume":"96","author":"D Lyons","year":"1997","unstructured":"Lyons D, Roy S, O\u2018Byrne S, Swift CG: ACE inhibition: postsynaptic adrenergic sympatholytic action in men. Circulation 1997, 96:911\u2013915.","journal-title":"Circulation"},{"key":"67_CR28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000139534","volume":"55","author":"EH Ohlstein","year":"1997","unstructured":"Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997, 55:244\u2013251.","journal-title":"Pharmacology"},{"key":"67_CR29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00004872-200103000-00015","volume":"19","author":"JC Balt","year":"2001","unstructured":"Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA: Inhibition of angiotensin-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan and captopril. J Hypertens 2001, 19:465\u2013473.","journal-title":"J Hypertens"},{"issue":"suppl","key":"67_CR30","first-page":"R75","volume":"363","author":"JC Balt","year":"2001","unstructured":"Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA: Blockade of both pre-and post-synaptically located AT1 receptors by valsartan, candesartan, eprosartan and embusartan. Naunyn Schmiedeberg\u2018s Arch Pharmacol 2001; 363(suppl):R75.","journal-title":"Naunyn Schmiedeberg\u2018s Arch Pharmacol"},{"issue":"3","key":"67_CR31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0002-8703(99)70317-0","volume":"138","author":"DP Brooks","year":"1999","unstructured":"Brooks DP, Ohlstein EH, Ruffolo RR Jr: Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999, 138(3 Pt 2):246\u2013251.","journal-title":"Am Heart J"},{"key":"67_CR32","first-page":"175","volume":"260","author":"RM Edwards","year":"1992","unstructured":"Edwards RM, Aiyar N, Ohlstein EH, et al.: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK& F 108566. J Pharmacol Exp Ther 1992, 260:175\u2013181.","journal-title":"J Pharmacol Exp Ther"},{"key":"67_CR33","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00004872-199917010-00005","volume":"17","author":"DP Brooks","year":"1999","unstructured":"Brooks DP, Ruffolo RR Jr: Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J Hypertens Suppl 1999, 17:S27-S32.","journal-title":"J Hypertens Suppl"},{"key":"67_CR34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/080370599438293","volume":"8","author":"R Sega","year":"1999","unstructured":"Sega R: Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999, 8:114\u2013121.","journal-title":"Blood Press"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-001-0067-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0067-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:00Z","timestamp":1559434560000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-001-0067-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s11906-001-0067-x","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}